TY - JOUR
T1 - Antibody responses to Streptococcus Gallolyticus subspecies Gallolyticus proteins in a large prospective colorectal cancer cohort consortium
AU - Butt, Julia
AU - Blot, William J.
AU - Teras, Lauren R.
AU - Visvanathan, Kala
AU - Le Marchand, Loïc
AU - Haiman, Christopher A.
AU - Chen, Yu
AU - Bao, Ying
AU - Sesso, Howard D.
AU - Wassertheil-Smoller, Sylvia
AU - Ho, Gloria Y.
AU - Tinker, Lesley F.
AU - Peek, Richard M.
AU - Potter, John D.
AU - Cover, Timothy L.
AU - Hendrix, Laura H.
AU - Huang, Li Ching
AU - Waterboer, Tim
AU - Pawlita, Michael
AU - Epplein, Meira
N1 - Funding Information:
The NCI funds: this consortium (R01 CA190428, principal investigator: M. Epplein); the Southern Community Cohort Study (U01 CA202979, principal investigator: W.J. Blot); the NYU Women's Health Study; the NHS/HPFS (U01 CA167552; UM1 CA186107; P01 CA087969; and UM1 CA167552); the PHS (R01 CA097193; R01 CA040360; and R01 HL034595); and the MEC (U01 CA164973, principal investigator: L. Le Marchand). R.M. Peek is supported by R01 DK058587 and R01 CA077955. T.L. Cover is supported by NIH R01 AI039657, R01 AI118932, P01 CA116087 and the Department of Veterans Affairs BX000627. The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services through contracts, HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. The development of H. pylori multiplex serology was funded in part by the Joint Initiative for Innovation and Research of the German Helmholtz Association. CLUE thank the participants and staff for their contributions, as well as the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Department of Health and Mental Hygiene (http://phpa.dhmh.maryland.gov/cancer).
Funding Information:
The NCI funds: this consortium (R01 CA190428, principal investigator: M. Epplein); the Southern Community Cohort Study (U01 CA202979, principal investigator: W.J. Blot); the NYU Women's Health Study; the NHS/HPFS (U01 CA167552; UM1 CA186107; P01 CA087969; and UM1 CA167552); the PHS (R01 CA097193; R01 CA040360; and R01 HL034595); and the MEC (U01 CA164973, principal investigator: L. Le Marchand). R.M. Peek is supported by R01 DK058587 and R01 CA077955. T.L. Cover is supported by NIH R01 AI039657, R01 AI118932, P01 CA116087 and the Department of Veterans Affairs BX000627. The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services through contracts, HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. The development of H. pylori multiplex serology was funded in part by the Joint Initiative for Innovation and Research of the German Helmholtz Association. CLUE thank the participants and staff for their contributions, as well as the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Department of Health and Mental Hygiene (http://phpa.dhmh.Maryland.gov/cancer).
Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2018/10
Y1 - 2018/10
N2 - Background: Antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG) proteins, especially pilus protein Gallo2178, have been consistently associated with colorectal cancer risk. Previous case-control studies and prospective studies with up to 8 years of follow-up, however, were unable to decipher the temporality of antibody responses to SGG in the context of the long-term multistep development of colorectal cancer. In this study, we analyzed a large U.S. colorectal cancer cohort consortium with follow-up beyond 10 years for antibody responses to SGG. Methods: We applied multiplex serology to measure antibody responses to 9 SGG proteins in participants of 10 prospective U.S. cohorts (CLUE, CPSII, HPFS, MEC, NHS, NYUWHS, PHS, PLCO, SCCS, and WHI) including 4,063 incident colorectal cancer cases and 4,063 matched controls. Conditional logistic regression was used to assess whether antibody responses to SGG were associated with colorectal cancer risk, overall and by time between blood draw and diagnosis. Results: Colorectal cancer risk was increased among those with antibody responses to Gallo2178, albeit not statistically significant [OR, 1.23; 95% confidence interval (CI), 0.99- 1.52]. This association was stronger for cases diagnosed <10 years after blood draw (OR, 1.40; 95% CI, 1.09-1.79), but was not found among cases diagnosed ≥10 years after blood draw (OR, 0.79; 95% CI, 0.50-1.24). Conclusions: In a large cohort consortium, we reproduced the association of antibody responses to SGG Gallo2178 with colorectal cancer risk for individuals diagnosed within 10 years after blood draw. Impact: This timing-specific finding suggests that antibody responses to SGG are associated with increased colorectal cancer risk only after tumorigenesis has begun.
AB - Background: Antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG) proteins, especially pilus protein Gallo2178, have been consistently associated with colorectal cancer risk. Previous case-control studies and prospective studies with up to 8 years of follow-up, however, were unable to decipher the temporality of antibody responses to SGG in the context of the long-term multistep development of colorectal cancer. In this study, we analyzed a large U.S. colorectal cancer cohort consortium with follow-up beyond 10 years for antibody responses to SGG. Methods: We applied multiplex serology to measure antibody responses to 9 SGG proteins in participants of 10 prospective U.S. cohorts (CLUE, CPSII, HPFS, MEC, NHS, NYUWHS, PHS, PLCO, SCCS, and WHI) including 4,063 incident colorectal cancer cases and 4,063 matched controls. Conditional logistic regression was used to assess whether antibody responses to SGG were associated with colorectal cancer risk, overall and by time between blood draw and diagnosis. Results: Colorectal cancer risk was increased among those with antibody responses to Gallo2178, albeit not statistically significant [OR, 1.23; 95% confidence interval (CI), 0.99- 1.52]. This association was stronger for cases diagnosed <10 years after blood draw (OR, 1.40; 95% CI, 1.09-1.79), but was not found among cases diagnosed ≥10 years after blood draw (OR, 0.79; 95% CI, 0.50-1.24). Conclusions: In a large cohort consortium, we reproduced the association of antibody responses to SGG Gallo2178 with colorectal cancer risk for individuals diagnosed within 10 years after blood draw. Impact: This timing-specific finding suggests that antibody responses to SGG are associated with increased colorectal cancer risk only after tumorigenesis has begun.
UR - http://www.scopus.com/inward/record.url?scp=85054352100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054352100&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-18-0249
DO - 10.1158/1055-9965.EPI-18-0249
M3 - Article
C2 - 30038049
AN - SCOPUS:85054352100
SN - 1055-9965
VL - 27
SP - 1186
EP - 1194
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 10
ER -